On Thursday, Cathie Wood-led Ark Invest made significant trades involving Tempus AI Inc and GitLab Inc. These trades reflect Ark’s strategic positioning in the tech and AI sectors, following recent earnings reports from both companies.
Ark Invest’s ARK Innovation ETF acquired 225,833 shares of Tempus AI, while ARK Genomic Revolution ETF purchased 44,969 shares. The transactions were valued at $13.23 million. For the day, Tempus AI shares ended 7.9% lower at $48.86.
These trades come after Tempus AI’s recent quarterly earnings report, which showed a revenue miss but an earnings-per-share beat. The company reported fourth-quarter revenue of $200.68 million, falling short of the $203.12 million estimate. However, its adjusted loss of 18 cents per share was better than the anticipated 20-cent loss.
Despite the mixed results, Tempus AI provided strong guidance. Analysts have varied opinions on Tempus AI, with some expressing bullish sentiments while others remaining cautious.
On the same day, Ark Invest’s ARKK and ARK Next Generation Internet ETF collectively purchased 86,906 shares of GitLab. This trade was valued at $5.06 million based on Thursday’s closing price of $58.25.
This move follows GitLab’s impressive fourth-quarter earnings report, which exceeded expectations. GitLab reported earnings of 33 cents per share, surpassing the consensus estimate of 23 cents. Additionally, its revenue of $211.43 million beat the expected $206.12 million.
Purchased Ibotta Inc. (IBTA) stock through ARKK and ARKF
Purchased Recursion Pharmaceuticals Inc. (RXRX) shares through ARKG.
Sold shares of Uipath Inc. (PATH) via ARKK and Draftkings Inc. (DKNG) through ARKW.
ARKG sold Repare Therapeutics Inc. (RPTX) and Exact Sciences Corp. (EXAS) stock
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。